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Abstract 
Background: Non-alcoholic fatty liver disease is one of the most 
common chronic liver diseases. Given the lack of definitive 
documentation for the effect of thyroid gland disorders on fatty liver, 
this study was conducted to determine the relationship between serum 
thyroid hormones levels and fatty liver in patients referring to Imam 
Hossain Hospital in Shahroud, in 2016. 
Methods: This case-control study was performed on 150 patients. The 
case group consisted of fatty liver patients whose disease was 
diagnosed based on laboratory and ultrasound findings, and a control 
group of patients with any other diseases without fatty liver. After liver 
ultrasonography, blood samples were taken from all patients and 
thyroid hormones levels were measured. 
Results: Of the 150 patients examined, the mean BMI of the patients 
was 24.79±6.9 kg / m2, which was significantly higher in the case 
group (P<0.012). The mean FBS level, was 131.5±83.5 mg / dl, which 
was significantly higher (P<0.001) in the case group. Similarly, the 
mean of TG was 245.5±128.5 mg / dl, which was significantly higher in 
the case group (P<0.047). On the other hand, the mean LDL of 
patients was 145.5±30.5 mg / dl, which was significantly higher 
(P<0.012) in patients with fatty liver. Further, the mean TSH of 
patients was significantly higher in the case group (P<0.014). Finally, 
there were no significant differences between the two groups regarding 
other variables. 
Conclusions: The results of this study suggested that thyroid gland 
disorders, especially hypothyroidism, were significantly higher in 
patients with fatty liver than in other patients. Nevertheless, they could 
not be influential in the incidence, exacerbation and persistence of fatty 
liver as a favorable factor. 
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Introduction 
Fatty liver disease (FLD) refers to a spectrum of clinical 
and pathological conditions which is due to the deposition of 
fat droplets in the liver of patients who have no history of 
alcohol consumption. This condition ranges from simple 
steatos to liver disease such as non-alcoholic steatohepatitis, 
fibrosis, cirrhosis, and eventually hepatocellular cancers.1-2 The 
natural liver contains 5 grams of fat per 100 grams of its 
weight, but if the fat content exceeds 5 to 10% of the liver's 
weight, the person has a FLD.3 Fatty liver is one of the most 
common liver diseases in the world whose prevalence varies 
from region to region. The prevalence of this disease is 
estimated to be between 7% and 40% in Asian regions. The 
outbreak of FLD in western developed countries has been 
reported to be 2 to 3 times more than that of hepatitis B and C 
and alcohol-related liver disease; it is the most common cause 
of liver tests disorders.1-3 The symptoms are non-specific and 
include fatigue, lethargy, and pain in the upper right abdomen; 
the patients may not be aware of their illness or it may be 
accidentally discovered in abdominal ultrasound or other 
examinations.4 Risk factors associated with this disease 
include: increased age, high weight, abdominal obesity, 
abnormal blood lipids profiles, high blood pressure, high blood 
sugar, insulin resistance and metabolic syndrome, cigarette, and 
non-standard diet.5 Also, taking medications such as 
corticosteroids, aspirin, methotrexate, tamoxifen, tetracycline, 
valproic acid, amiodarone, a well as viruses can also lead to 
this complication, but the main risk factor is diabetes and 
resistance to insulin.6-7 Hormonal disorders are one of the risk 
factors that can affect the development and exacerbation of 
fatty liver. Thyroid gland disorders are one of the most 
common disorders.7 Different studies worldwide have reported 
different rates of thyroid dysfunction. The range of these 
figures has been different from 1% to more than 20% in the 
hypothyroidism and hyperthyroidism.8 Hypothyroidism is an 
endocrine disorder which gradually decreases thyroid function 
by inducing self-immune processes.8-9 Hypothyroidism is one 
of the risk factors for ischemic cardiovascular disease. In 
hypothyroidism, atherogenic lipid disorders may be observed 
causing coronary artery obstruction.10 On the other hand, in 
hyperthyroidism, with increased appetite and higher levels of 
food intake, there is a risk of lipid profile disorders.11 Thyroid 
hormones play an important role in energy homeostasis and 
body weight. As hyperthyroidism triggers appetite and 
hypothyroidism with weight gain, the details and mechanism of 
association between thyroid hormone and lipid metabolism has 
been are important to be scrutinized.11-12 
Given the complications of thyroid dysfunction, especially 
hypothyroidism, such as overweight, obesity, impaired glucose 
and fat metabolism, and lack of mobility known as the risk 
factors for fatty liver, it is therefore conceivable that thyroid 
hormones and especially TSH levels may affect the incidence 
of fatty liver.13-14 The best diagnostic test for non-alcoholic 
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liver fatty liver is biopsy,9-10 but ethical and medical 
considerations have limited its usage in patients. Increased liver 
enzymes are commonly found in these patients, but the 
characteristics of these tests are low. Therefore, clinical 
evaluation of non-alcoholic fatty liver was performed based on 
a combination of ultrasound findings and laboratory tests. 
Because of sparse studies in Iran regarding the effect of thyroid 
hormone function on the development of fatty liver and the 
association of this disorder with other risk factors, it is 
necessary to study it in patients with fatty liver. Accordingly, 
this study was conducted to determine the relationship between 
serum levels of T3, T4 and TSH and fatty liver in patients 
referring to Imam Hossain Hospital of Shahroud in 2016. 
Materials and Methods  
This research is a case-control study conducted among 
patients referring to Imam Hossain Hospital of Shahroud 
(Northeastern of Iran) between January and December 2017. 
The case group was selected from patients with non-alcoholic 
liver disease diagnosed based on liver tests and sonography of 
their disease and categorized further. 
Mild fatty liver: a brief increase in liver echogenicity where 
the diaphragm and vascular wall are well visible in ultrasound 
(grade 1). 
Medium fatty liver: moderate increase in liver echogenicity 
where the diaphragmatic view and the intra-liver vessel wall 
are slightly disturbed in ultrasound (grade 2). 
Sever fatty liver: increased liver echogenicity where the 
posterior lobe of the liver disappears in ultrasound while the 
diaphragm and the wall of the intra-liver vessel is barely visible 
or even unobservable (grade 3).9 
The control group chosen had no symptoms in ultrasound 
and liver tests in favor of the fatty liver and referred to the 
ultrasound section for other reasons. 
None of the patients and controls did not have liver disease, 
malignancy, chemotherapy, diabetes, thyroid hormonal 
disorders, pregnancy, and had no history of taking 
corticosteroids and alcohol over the past year.  
Exposure and main predictor variables were age, sex, BMI, 
fasting blood glucose, triglyceride, total cholesterol, HDL-
LDL, liver enzymes, T3, T4, and TSH.  
Descriptive statistics including mean and standard 
deviation, as well as relative frequency were used to describe 
the data. To examine the relationships and comparisons 
between the two groups, the chi-square test was used for 
qualitative variables and t test for quantitative variables. 
Further, multiple logistic regression was employed to evaluate 
the odds of each of the variables. All analyses were performed 
using SPSS software version 16 with significance level 
considered P<0.05. The sample size using Epi info 7.2 at a 
significance level of 5% and a power of 80%, equaled 75 
subjects in each group totally amounting to 150. 
This study received an ethics code number 
(IR.SHMU.REC. 1395.95) from research deputy of Shahroud 
University of Medical Sciences. The essential information and 
the objectives of the study were explained to the patients, and 
written consent was obtained for participation in the study. 
Results 
In this study, 51 (34.0%) of the participants were male. The 
mean age of the all patients was 57.63±28.03 years, where 
there was no significant difference between the two groups. 
The mean BMI of the case group was 25.19±6.52 kg/m2 and 
that of the control group was 24.21±6.83 kg/m2, which was 
significantly higher in the case group (P=0.012). The mean 
TSH level in the case group was 4.8±2.1 ng/dl and in the 
control group 1.9±0.8 ng/dl, which was significantly higher in 
the case group (P=0.014). The results of biochemical and liver 
tests of patients in the two groups are reported in table 1. In this 
study, the relationship between predictor variables and FLD 
was investigated using a multiple regression model. As 
provided in table 2, the fatty liver outcome was significantly 
associated with LDL (P<0.001), triglyceride (P<0.043), and 
FBS (P<0.001) while there was no significant relationship with 
other variables. The results of the multivariate logistic 
regression model are presented in table 2. 
Table 1. Results of biochemical and liver tests in two groups 
Lab Test 
Case group 
Mean±SD 
Control group 
Mean±SD 
Total 
Mean±SD 
P.V 
Fasting blood sugar (mg/dl) 137.5±53.5 124.5±62.5 128.5±59.5 0.001 
Triglyceride (mg/dl) 223.5±130.5 218.5±125.5 220.5±128.5 0.047 
Total cholesterol (mg/dl) 318.3±155.5 265.5±144.5 284.5±151.5 0.051 
LDL cholesterol (mg/dl) 175.3±65.5 125.5±42.5 155.5±53.5 0.012 
HDL cholesterol (mg/dl) 39.5±6.8 44.5±5.5 42.8±5.3 0.109 
TSH (ng/ml) 4.8±2.1 1.9±0.8 3.1±1.3 0.014 
AST (IU/L) 95.3±32.5 29.5±6.5 63.5±15.8 0.001 
ALT (IU/L) 108.5±28.5 37.5±7.4 75.4±20.8 0.001 
ALK-P (IU/L) 380.5±75.5 295.5±45.5 345.4±58.2 0.003 
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Table 2. Relationship between independent variables with fatty liver in multiple logistic regression model 
Independent variables Odds Ratio 95% Confidence Interval P.V 
Age category 
Less than 30 years 
30 to 50 years 
More than 50 years 
1.00 
1.08 
1.09 
 
0.06-1.34 
0.07-1.45 
 
0.065 
0.055 
Sex 
Male 
Female 
1.00 
0.79 
 
0.61-1.01 
 
0.069 
History of diabetes mellitus 
Negative 
Positive 
1.00 
1.11 
 
0.81-1.25 
 
0.063 
Body mass index (kg/m2) 
18-25 
<18 
>25 
1.00 
0.72 
1.37 
 
0.56-0.99 
0.91-1.73 
 
0.059 
0.023 
Triglyceride (mg/dl) 
<150 
>150 
1.00 
1.15 
 
0.87-1.32 
 
0.043 
Total cholesterol (mg/dl) 
<180 
>180 
1.00 
1.33 
 
1.11-1.54 
 
0.052 
LDL cholesterol (mg/dl) 
<130 
>130 
1.00 
1.49 
 
1.22-1.76 
 
0.001 
HDL cholesterol (mg/dl) 
>40 
<40 
1.00 
1.03 
 
0.86-1.28 
 
0.079 
Fasting blood sugar (mg/dl) 
<126 
>126 
1.00 
1.55 
 
1.26-1.85 
 
0.001 
TSH (ng/dl) 
1.5-5 
<1.5 
>5 
1.00 
1.08 
1.43 
 
0.85-1.22 
1.16-1.73 
 
0.068 
0.051 
 
Discussion 
The results of this study revealed that predictor variable 
such as BMI, LDL, triglyceride, and fasting blood glucose had 
a significant relationship with fatty liver, while other predictor 
variables such as age, sex, triglyceride, HDL, chol, diabetes, 
TSH were not significantly correlated with the outcome in 
logistic regression model. According to logistic regression 
model findings, thyroid gland dysfunction (TSH level) did not 
increase the risk of fatty liver and there was no significant 
relationship between the changes in this hormone and fatty 
liver disease. This finding was in line with the results of 
Pearce’ study who concluded that there is an association 
between hypothyroidism and fatty liver disease.15 
In a study by Duntas et al., it was found that more than 
50% of these patients had varying degrees of impairment in fat 
profile where hypercholesterolemia and hypertriglyceridemia 
levels were higher in them. However, no significant 
relationship was found between thyroid gland disorders and 
non-alcoholic fatty liver, which is in perfect agreement with the 
present study findings.16 
The results of this study suggested that changes in thyroid 
hormones, especially hypothyroidism, can significantly 
increase the chance of developing fatty liver. This finding is 
consistent with the results of Kim et al. study.17 They found that 
the reason may be due to decreased metabolism of the body 
and consequently diminished mobility, increased body mass 
index, and fat accumulation in different tissues and especially 
in the liver.  
In a study by Ludwig et al., who researched the risk factors 
affecting fatty liver, variables such as age, waist circumference, 
BMI, FBS, triglyceride, and cholesterol showed a significant 
correlation with the incidence of fatty liver; the significance of  
 
all these variables was well consistent with the present study 
results.18 
In the study of Shiva Kumar et al., which was performed on 
350 patients with fatty liver, parameters such as weight gain 
and obesity, lipid profiles, glucose levels, and hormonal 
disorders, especially hypothyroidism, were studied. It was 
found that all of these factors can be associated with the 
development of a fatty liver as an independent factor, but there 
was no statistically significant difference between the groups. 
Again, this finding is consistent with the results of the present 
study.19 
As observed, the present study revealed a strong 
relationship between obesity as well as overweight and the 
incidence of fatty liver disease. Fat tissue storage and release of 
energy in the form of triglycerides during excessive 
consumption of food and hunger can be one of the most 
important factors in this regard.20 Further, fat tissue produces 
hormones such as leptin, adiponectin, and pro-inflammatory 
cytokines such as interleukin-6 and alpha-tumor necrosis 
factor. Increased levels of obesity and obesity lead to 
imbalance of hormones and cytokines. In response, the 
inflammatory mechanisms and insulin resistance increase, 
especially in the liver thereby raising the risk of hepatic 
steatosis and nonalcoholic fatty liver.20-22 
Since the efficacy and safety of drug therapy in patients 
with non-alcoholic fatty liver is not definitively known, 
lifestyle changes, diet modifications, and weight loss are 
commonly used treatments for non-alcoholic liver fatty acids; 
5-10% weight loss can dramatically improve the metabolic 
function of the liver.23- 24 
The results of this study suggested that changes in TSH 
level were significantly higher in patients with fatty liver than 
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in other patients. However, this factor was not confirmed as a 
contributing factor in the incidence, exacerbation, and 
persistence of fatty liver. In order to fully confirm this, more 
research is required with a larger sample size. Therefore, all 
patients with fatty liver requiring attention to hormonal 
disorder and lifestyle changes, should be carefully evaluated 
for thyroid disorder and, if such findings are detected, be 
corrected as soon as possible. 
The limitations of this research included the impossibility 
of a biopsy to confirm the ultimate fatty liver (due to ethical 
barriers) and self-declaration of patients about chronic diseases. 
By performing accurate and complete liver ultrasonography, 
along with relevant tests and completely explaining the 
research purposes for patients, attempts were made to offset 
this limitation. 
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